WinstonWınston
Doximity logo

Doximity

DOCS
60
Medical - Healthcare Information Services · Healthcare
Price
$21.52
-0.69 (-3.11%)
Market Cap
$4.02B
Winston Score
60
Winston is curious
A decent business — some strong pillars, some weaker.

Share count rising — dilution

+4.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 191.0M (2022) → 199.0M (2026)

Doximity runs a private online network built specifically for doctors and other medical professionals in the United States. Its main product is a platform where physicians can message each other securely, read medical news, conduct telehealth video visits with patients, and manage their careers. It is often described as a "LinkedIn for doctors" and claims to have over 80% of U.S. physicians as members.

The company makes most of its money by charging pharmaceutical companies and health systems to advertise and communicate directly with doctors through the platform. Doximity operates almost entirely in the United States and generates very high profit margins, reflecting its low cost of delivering a software product to an already-large user base. Its main competitive advantage is the size of its physician network, since a platform becomes more useful as more doctors join it. The key risk is that large technology companies or other health platforms could build competing networks and attract doctors away over time.

Winston Score History

Politician Trades

6 trades / 12mo

2 Congressional buys and 4 sells on DOCS in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-69.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$131M/ year

Rising (+40% vs prior year)

20.3% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

3.0%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$219M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Doximity is putting 20% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
86.7%
Premium pricing power — 86.7% gross margin
Operating Margin
17.1%
Healthy — 17.1% operating margin
ROCE
2.6%
Weak — 2.6% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+11.9%
Steady sales growth (11.9% YoY)
EPS YoY
-4.4%
Earnings shrinking (-4.4% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
177%
Turns 177% of profit into real cash
FCF Margin
56.0%
Converts sales into free cash efficiently (56.0%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.01
Conservative — low debt load (0.01)
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
19.7x
Fair value — P/E 19.7

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
+7.5
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (19.7 → 12.3)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial